Hypothesis

Baseline fecal ratio of butyrate to secondary bile acids (deoxycholic acid, lithocholic acid) predicts the magnitude of HPA axis normalization and depressive symptom improvement after an 8‑week personalized psychobiotic regimen.

Mechanistic Rationale

Butyrate acts as a histone deacetylase inhibitor, boosting BDNF transcription in hippocampal neurons and promoting microglial quiescence via GPR109A signaling[https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2025.1697200/full]. Secondary bile acids activate TGR5 receptors on enteroendocrine L‑cells, stimulating GLP‑1 release that enhances vagal afferent firing and downstream anti‑inflammatory signaling[https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1664800/full]. An elevated butyrate/secondary bile acid ratio therefore shifts the gut‑derived signal from pro‑inflammatory (bile‑acid‑driven) to neuroprotective (butyrate‑driven), priming the brain for psychobiotic benefit.

When this ratio is low, excess secondary bile acids sustain TLR4‑mediated NF‑κB activation in intestinal macrophages, increasing circulating IL‑6 and TNF‑α that blunt BDNF expression and sustain HPA axis hyperactivity[https://pmc.ncbi.nlm.nih.gov/articles/PMC12883760/]. In such a milieu, adding probiotics or prebiotics alone cannot overcome the bile‑acid‑driven inflammatory tone, explaining trial heterogeneity.

Testable Predictions

1. Participants with a baseline butyrate/secondary bile acid ratio above the cohort median will show ≥30 % greater reduction in cortisol awakening response and ≥4‑point drop in MADRS scores compared with those below the median after the same psychobiotic protocol.
2. Experimental elevation of the ratio (via oral butyrate supplementation combined with a bile‑acid‑sequestrant diet) in low‑ratio individuals will convert non‑responders into responders, as measured by HPA axis normalization and increased hippocampal BDNF peripherally (exosome‑associated).
3. Conversely, pharmacologic TGR5 antagonism in high‑ratio participants will attenuate the psychobiotic effect, confirming the bile‑acid arm’s modulatory role.

Experimental Design

• Population: 120 adults with moderate‑to‑severe depression (MADRS ≥ 20) screened for baseline fecal metabolomics (SCFA and bile acid profiling).
• Stratification: Split into high‑ratio (≥median) and low‑ratio (<median) groups.
• Intervention: 8‑week personalized psychobiotic cocktail (Lactobacillus helveticus R0052, Bifidobacterium longum R0175, galactooligosaccharides) identical for all.
• Arms: Within each ratio stratum, randomize to psychobiotic vs. placebo (double‑blind).
• Outcomes: Primary – change in cortisol awakening response; secondary – MADRS, plasma IL‑6/TNF‑α, hippocampal‑derived exosome BDNF, fecal metabolomics pre/post.
• Analysis: Interaction term (ratio × treatment) in mixed‑effects model; a significant interaction supports the hypothesis.

Potential Pitfalls & Mitigations

• Variability in diet affecting bile acid pool: Standardize meals for 48 h before sample collection and provide low‑fat, high‑fiber run‑in diet.
• Confounding by antibiotic use: Exclude recent (<3 mo) antibiotic exposure.
• Measurement noise in bile acids: Use LC‑MS/MS with internal standards; run samples in duplicate.

If the interaction is null, the hypothesis is falsified, indicating that butyrate/secondary bile acid balance does not predict psychobiotic efficacy and that other microbial‑host axes dominate the gut‑brain signal in depression.